

THE VIEW

Life sciences | October 2020

Hi there,

The COVID-19 pandemic has caused the life sciences industry to unite in its plight to develop a cure for the deadly disease. In this month's newsletter, we take you through the significant pandemic-induced changes in the industry and a list of the major on-going vaccine trials. Furthermore, we present a post-COVID-19 outlook of healthcare market access strategies and recent developments in the industry.



The industry's COVID-19 response

Five major developments in the Life Sciences Industry over the past six months



The SARS-CoV-2 virus, which emerged as an unknown pneumonia-like disease in December 2019, gained the status of a global health crisis by March 2020. Lockdowns caused a temporary shutdown of labs and production facilities.

The industry's attention shifted towards developing a pandemic cure, which dampened the demand for non-pandemic products and trials. The industry had to ultimately find ways to adapt to the new normal

View: [Blog](#) | [Infographic](#)

Racing towards developing a vaccine

Since COVID-19 was declared as a pandemic, the life sciences industry has prioritized the search for its cure. Pharma and biotech companies are collaborating to speed up the R&D processes for both vaccines and other potential treatments.

Here is a list of the major ongoing vaccine trials that have shown positive results so far and have garnered the attention of medical experts across the globe, as of September 2020.

Vaccine developers	Clinical trial phase	Candidate Name	Vaccine type	Countries of trial
1 Novavax	Phase 3	NVX-CoV2373	Nanoparticle vaccine	UK
2 Sinovac	Phase 3	CoronaVac	Inactivated vaccine	Brazil, Indonesia, Turkey and Bangladesh
3 Johnson & Johnson* (J&J)	Phase 3	JNJ-78436735	Non-replicating viral vector	US, Argentina, Brazil, Chile, Colombia, Mexico, Peru, and South Africa
4 CanSino Biologics	Phase 3	Ad5-nCoV	Recombinant vaccine	Pakistan, Russia
5 AstraZeneca (AZ) and Oxford University (with Serum Institute and Iqvia)**	Phase 3	AZD1222	Replication-deficient viral vector	UK, US, India, Brazil and South Africa
6 Moderna and NIH	Phase 3	mRNA-1273	mRNA based	US
7 Pfizer and BioNTech	Phase 3	BNT162	mRNA based	US, Argentina, Brazil, South Africa and Germany
8 Sinopharm and Wuhan Institute of Biological Products	Phase 3	-	Inactivated vaccine	Peru, Morocco and UAE
9 Bharat Biotech and National Institute of Virology	Phase 2 (human trials)	Covian	Inactivated vaccine	India
10 GSK and multiple partners (Sanofi and Clover)	Phase 1/2 (with Sanofi)	-	Protein vaccine (with Sanofi)	USA
	Phase 1 (Human trials-with Clover)	SCB-2019	Adjuvanted vaccine (with Clover)	Australia, UK


Note:

*As of 13 Oct 2020, Johnson & Johnson paused its Phase 3 trial to investigate an adverse reaction in a volunteer

**AZ paused its trial as of 6 Sep 2020. The trial has resumed in only the UK as of 12 Sep 2020

References: [1](#), [2](#), [3](#), [4](#), [5](#), [6](#), [7](#), [8](#), [9](#), [10.1](#), [10.2](#)

Reimagining healthcare market access strategies



The current pandemic has led to a period of continued uncertainty across global healthcare markets, increasing the barriers to market access. We've outlined the key challenges facing market access strategists and trends that will impact future strategies.

[Read more.](#)

In the news

Post pandemic outlook

Healthcare market will perform well post COVID-19 ([bloomberg](#))

Post-COVID-19 patient experience: how healthcare has changed ([forbes](#))

GSK CEO says COVID-19 is pharma's chance at redemption ([fiercepharma](#))

Acquisitions & Partnerships

Gilead to buy cancer drugmaker Immunomedics for USD 21B ([biopharmadive](#))

Roche acquired biotech firm Inflazome for USD 449M ([biopharmadive](#))

Sanofi partners with Health2Sync for diabetes digital solution ([mobihealthnews](#))

Subscribe to our newsletter

Netscribes helps technology firms build a competitive advantage through actionable data and insights. To schedule a consultation, [contact us](#)

41 East, 11th Street, New York
NY10003, USA
+1-877-777-6569
info@netscribes.com



This email was sent to marketing@netscribes.com
You received this email because you are registered with Netscribes
[Unsubscribe here](#)

© 2020 Netscribes